BreAking the Link betweeN myo10 and CancEr

Projektinformationen

BALaNCE

ID Finanzhilfevereinbarung: 641346

DOI

10.3030/641346

Projekt abgeschlossen

EK-Unterschriftsdatum 20 April 2015

Startdatum 1 Mai 2015

Enddatum 31 Oktober 2016

Finanziert unter

• EXCELLENT SCIENCE - European Research Council (ERC)

Gesamtkosten

€ 150 000,00

EU-Beitrag

€ 150 000,00

Koordiniert durch

TURUN YLIOPISTO
Finland

Periodic Reporting for period 1 - BALaNCE (BreAking the Link betweeN myo10 and CancEr)

Berichtszeitraum: 2015-05-01 bis 2016-10-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Metastasis is the main cause for cancer morbidity as spread of the cancer cells from their primary site to distant organs is currently difficult, or impossible, to treat. We have found earlier that several proteins regulating actin-rich protrusions, called filopodia, are overexpressed in spreading cancers, like breast and pancreatic cancers. One of the proteins driving these filopodia is Myo10, an actin and integrin binding motor protein. The aim of this project was to generate solid evidence that inhibiting Myo10 is an effective strategy to combat cancer spread. During this project we have used drug screening and different cancer metastasis models and validated that indeed Myo10 inhibition is a viable option for cancer therapy. As an outcome we have secured a partnership to start developing new Myo10 inhibitors against cancer.